Respiratory research funding is inadequate, inequitable, and a missed opportunity

Siân Williams, Aziz Sheikh, Harry Campbell, Neil Fitch, Chris Griffiths, Robert S Heyderman, Rachel E Jordan, S Vittal Katikireddi, Ioanna Tsiligianni, Angela Obasi

Research output: Contribution to journalLetterpeer-review

Abstract / Description of output

COVID-19 has placed respiratory medicine at the centre of health responses worldwide, but lung health was a major global challenge long before the current pandemic. More than 1000 people die of asthma and more than 2000 children die of pneumonia daily, and lung cancer is the most common cancer type in terms of incidence and mortality. Most of this enormous burden has fallen on people in the south and vulnerable populations in high-income economies. These are diseases of poverty, and disadvantages further compound inequity through increased disability, loss of productivity, and high health costs.1 As a major driver of ill health and poverty, the burden of respiratory disease remains a global rate-limiting step towards achieving health equity, economic growth, and Sustainable Development Goals.2
Original languageEnglish
Pages (from-to)e67-e68
JournalThe Lancet Respiratory Medicine
Issue number8
Publication statusPublished - 4 Aug 2020


Dive into the research topics of 'Respiratory research funding is inadequate, inequitable, and a missed opportunity'. Together they form a unique fingerprint.

Cite this